{
    "clinical_study": {
        "@rank": "158206", 
        "brief_summary": {
            "textblock": "Cross-sectional study, observation made by healthcare professionals of subjects or\n      caregivers, administering romiplostim at their first standard-of-care visit 4 weeks after\n      training with the home administration training pack. Further observations can also be\n      recorded in the study if made within 16 weeks of enrolment. Data will be collected from the\n      subjects' dose diary at their first standard of care visit to ensure there were no problems\n      with administration while not at the clinic."
        }, 
        "brief_title": "Study of Patients With ITP Estimating the Proportion Administering Romiplostim Correctly After Receiving Home Admin Training", 
        "completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Immune Thrombocytopenic Purpura", 
        "condition_browse": {
            "mesh_term": [
                "Purpura", 
                "Purpura, Thrombocytopenic", 
                "Purpura, Thrombocytopenic, Idiopathic"
            ]
        }, 
        "detailed_description": {
            "textblock": "This cross-sectional study involves direct observation by a healthcare professional of a\n      series of subjects and caregivers in the act of administering romiplostim at their first\n      standard-of-care visit occurring 4 weeks after training with the HAT pack. Further\n      observations, if they occur, will also be recorded in the study if made within 16 weeks of\n      enrolment. (Additional observations are voluntary and are not required for study\n      participation; they occur only if the healthcare professional requests them.) Additionally,\n      data will be collected from the subjects' dose diary at the first standard of care visit to\n      ensure there were no problems with administration while not at the clinic."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  (1) adult ITP patient, treated per EU Summary of product characteristics (SmPC), or\n             caregiver new (or at least a 3 month gap) to administering romiplostim,\n\n          -  (2) has received HAT pack training,\n\n          -  (3) available at standard-of-care medical visit 4 weeks (range 2 to 8 weeks) after\n             HAT pack training,\n\n          -  (4) patient provides informed consent."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "ITP patients being treated with romiplostim will be approached for possible study\n        participation. At each participating site, patients that meet the following criteria will\n        be  enrolled as a study subject.  Adult ITP patients, treated per EU Summary of product\n        characteristics (SmPC), or caregiver new (or at least a 3 month gap) to administering\n        romiplostim, that has received HAT pack training and is available at a standard-of-care\n        medical visit 4 weeks (range 2 to 8 weeks) after HAT pack training, the patient provides\n        informed consent."
            }
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 11, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02085993", 
            "org_study_id": "20120269"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "romiplostim,", 
            "Nplate,", 
            "immune thrombocytopenic purpura"
        ], 
        "lastchanged_date": "April 25, 2014", 
        "link": {
            "description": "AmgenTrials clinical trials website", 
            "url": "http://www.amgentrials.com"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Cross-sectional Study of Patients With Immune Thrombocytopenic Purpura and Caregivers to Estimate the Proportion Who Administer Romiplostim Correctly After Receipt of Home Administration Training Materials", 
        "overall_contact": {
            "last_name": "Amgen Call Center", 
            "phone": "866-572-6436"
        }, 
        "overall_official": {
            "affiliation": "Amgen", 
            "last_name": "MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Austria: Ethikkommission", 
                "Belgium: Institutional Review Board", 
                "Netherlands:  Independent Ethics Committee", 
                "United Kingdom: Research Ethics Committee", 
                "France: Comit\u00e9 consultatif sur le traitement de l'information en mati\u00e8re de recherche dans le domaine de la sant\u00e9", 
                "Greece: National Organization of Medicines", 
                "Spain: Ministry of Health", 
                "Germany: Ethics Commission"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "to estimate the proportion of subjects and caregivers who administer romiplostim correctly after being trained with the HAT pack.", 
            "measure": "Successful self administration of romiplostim", 
            "safety_issue": "Yes", 
            "time_frame": "First Standard of Care visit post Home Administration Training (range 2-8 weeks)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02085993"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To estimate the proportion of subjects and caregivers who reconstitute romiplostim correctly.", 
                "measure": "successful reconstitution of romiplostim", 
                "safety_issue": "No", 
                "time_frame": "First Standard of Care visit post Home Administration Training (range 2-8 weeks)"
            }, 
            {
                "description": "A yes/no indicator of whether the subject or caregiver injects romiplostim successfully with the difference between the prescribed and administered dose expressed as a %", 
                "measure": "Accuracy in administering the prescribed dose of romiplostim", 
                "safety_issue": "No", 
                "time_frame": "First Standard of Care visit post Home Administration Training (range 2-8 weeks)"
            }, 
            {
                "description": "A Yes/No indicator for whether the subject or caregiver administers romiplostim correctly at any follow up visits.", 
                "measure": "Successful administration of romiplostim at follow up visits", 
                "safety_issue": "No", 
                "time_frame": "Up to 16 weeks post enrolment"
            }
        ], 
        "source": "Amgen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Amgen", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2014", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}